• Post-partum depression (PPD) affects 1 in 8 women

• PPD has consequences for both mother and child

     • Negatively impacts breastfeeding, sleep routines, well-child visits, vaccinations, and safety practices

• Until recently, the primary treatment for PPD has been psychotherapy and antidepressants

• Brexanolone (generic for Zulresso) was FDA approved March 2019 and is the first drug approved specifically for PPD

     • 60-hour IV infusion

     • Neurosteroid and analogue of allopregnanolone

     • This medication offers a novel approach to treatment of postpartum depression